NCT05837052View on ClinicalTrials.gov

A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

May 15, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

December 30, 2026

Conditions
Unresectable Lung Non-Small Cell Carcinoma
Interventions
PROCEDURE

serplulimab plus chemotherapy as conversion treatment

Patients with unresectable NSCLC will receive serplulimab plus chemotherapy as conversion treatment, and then curative pneumonectomy will be provided for patients who are suitable for primary tumor resection. Locoregional ablative treatments will be performed for metastatic lesions.

Trial Locations (1)

310058

RECRUITING

Zhejiang University, Hangzhou

All Listed Sponsors
lead

Zhejiang University

OTHER